Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032?
When I started working in medical research, m...
Dr. Wolfgang Brysch
For this blog entry, we’ve been thinking: Is there a question that has been asked most frequently this year? And what does the answer say about our work at MetrioPharm?
The most frequently asked question clearly was: “Is MetrioPharm working on InflammAging?”
The so-call...
Dr. Wolfgang Brysch
We have spent this summer on the road. While the scientific team oversaw the progress of our Phase II clinical trial, our Business Development and Investor Relations staff introduced MetrioPharm AG to many different people: potential development partners, medical scientists, financial analysts, healthcare experts and investors.
Dr. Wolfgang Brysch
When I get this question – which happens a lot – I usually answer: ‘Yes, MetrioPharm has competition. And then again, no, MetrioPharm has no competition.’
On the one hand, there are drugs for chronic inflammatory diseases already approved today, and our MP1032 will be competing with them...
Dr. Wolfgang Brysch
Actually, it’s a routine question and I could have expected it. I was asked at our anniversary celebration last fall: “10 years of MetrioPharm – which one was the most difficult?” I had to think about that question for a moment. The year 2007 is not far in the past, still the difficulties of that time feel oddly distant now.
In 2008, right after the founding of the company, we were in...
Eva Brysch
Head of Investor Relations & Corporate Communications
invest@metriopharm.com
Ralf Haubert
Marketing Manager
blog@metriopharm.com
© MetrioPharm AG 2019
